Tyme Technologies (TYME) Announces Board Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil slips from five-month highs with Hormuz crossings, Russian sanctions waiver in focus
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Cerebras Systems falls as TD Cowen cuts price target
- Glass House Brands posts Q3 revenue of $56.8M, board member exits
- S&P 500, Nasdaq climb as AI-linked stocks recover ahead of earnings
- Nvidia wins CPU business from Modal, previously exclusive to AMD and Intel
TYME Technologies, Inc. Announces Changes to its Board of Directors
March 25, 2022 8:00 AM EDTIndustry veteran, Christine D. Baker, joins Board of Directors
Douglas A. Michels appointed Chairman of the Board
BEDMINSTER, N.J.--(BUSINESS WIRE)-- TYME Technologies, Inc. (Nasdaq: TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), today announced changes to its Board of Directors.
Christine D. Baker Named to Board of Directors
The Company is pleased to announce that Christine D. Baker has been appointed to TYMEs Board of Directors. Ms. Baker brings over 30 years of experience in the biotech/pharmaceutical industry, with expertise in... More



